Related Experiment Video
Updated: Jun 26, 2026
09:38
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
[Haemostatic aspects in clinical oncology]
F Langer1, K Holstein, B Eifrig
1Onkologisches Zentrum, II. Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf, Hamburg. langer@uke.uni-hamburg.de
Hamostaseologie
|January 10, 2009
Summary
Cancer patients often experience clotting disorders, with tissue factor (TF) playing a key role in tumor growth and metastasis. Low-molecular-weight heparin (LMWH) treats cancer-associated venous thromboembolism (VTE) and may aid cancer treatment.
Area of Science:
- Oncology
- Hematology
- Molecular Biology
Context:
- The link between cancer and thrombosis (blood clots) has been known since 1865.
- Clotting activation is crucial in venous thromboembolism (VTE) and disseminated intravascular coagulation in cancer patients.
- Hemostatic and fibrinolytic systems are implicated in tumor progression.
Purpose:
- To provide an overview of cancer-related clotting disorders.
- To discuss the pathogenesis and treatment of these disorders.
- To explore mechanisms by which hemostatic components drive tumor progression.
Summary:
- Tissue factor (TF) is involved in cancer growth and metastasis.
- Genetic events in tumorigenesis influence clotting disturbances in cancer.
- Low-molecular-weight heparin (LMWH) is standard for cancer-associated VTE and may offer adjunct cancer treatment benefits.
Impact:
- Highlights the dual role of hemostasis in cancer: VTE and tumor progression.
- Emphasizes the potential therapeutic role of LMWH beyond VTE treatment.
- Underscores the importance of understanding molecular mechanisms linking hemostasis and malignancy.
Related Concept Videos
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:05Introduction to Hemostasis
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...